MRNA: Moderna, Inc. - Summary | Jitta

Moderna, Inc.

NASDAQ:MRNA

Price
$434.04
Loss Chance
53.4%
2.84JITTA SCORE
> 1,000%Over Jitta Line
Jitta Ranking
246 / 1,076
2,485 / 4,656
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (34)
Recent Business Performance (86)
Financial Strength (56)
Return to Shareholders (13)
Competitive Advantage (42)
Jitta Signs
Recent IPOLess than 3 years
Operating MarginInconsistent
Recent Business PerformanceEarning decline 51.33% in the last year
CapExVery High
Key Stats
Jitta Score
Jitta Line
2.84
> 1,000%
1.41
210.31%
2.25
311.78%
Biotechnology
6.52
52.12%
5.19
46.36%
4.83
8.52%
COMPANY DESCRIPTION
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd.; Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group; Aldevron, LLC; Institute for Life Changing Medicines; and AbCellera Biologics Inc. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.